Lymphoma & CLL Therapeutics

Acalabrutinib meets primary endpoint in ELEVATE-RR trial for patients with R/R CLL

On January 25, 2021, it was announced that acalabrutinib has met its primary endpoint of non-inferior...

FDA approval of crizotinib for the treatment of pediatric patients and young adults with ALK-positive R/R ALCL

On January 14, 2021, it was announced that the U.S. Food and Drug Administration (FDA)...

Mosunetuzumab in heavily pretreated follicular lymphoma: Phase I dose-escalation trial updates

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub...

FDA places partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas

On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) has placed a partial...

What novel therapies are showing promise for patients with heavily pretreated MCL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael...

FDA accepts Investigational New Drug application for PBCAR19B for the treatment of R/R NHL

On January 19, 2021, it was announced that the U.S. Food and Drug Administration (FDA), accepted the...

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub...

Phase I trial of the triplet therapy ipilimumab, nivolumab, and brentuximab vedotin for patients with relapsed/refractory Hodgkin lymphoma

A summary of the results from a phase I clinical trial...